Roxithromycin (RU-28965) is an orally active semi-synthetic macrolide antibiotic. It inhibits protein biosynthesis in the elongation step by binding to the 50S bacterial ribosome. Roxithromycin exhibits antimicrobial, antiproliferative, anti-inflammatory, tumor vasculature inhibiting, and lung injury ameliorating effects.
- Inhibits protein biosynthesis by binding to 50S bacterial ribosome
- Active against Gram-positive and Gram-negative bacteria
- Displays antimicrobial, antiproliferative, and anti-inflammatory effects
- Inhibits tumor vasculature and ameliorates lung injury
- Reduces UVB-induced oxidative stress and keratinocyte apoptosis
- Induces apoptosis in senescent cells
- Protects against various bacterial infections in vivo
- Inhibits tumor angiogenesis and attenuates lung injury in animal models
- Modulates NF-κB and MAPK/ERK pathways